



TWO EMPLOYEES TERMINATED AFTER PARTICIPATING IN A SCHEME TO SELL MISBRANDED AND UNAPPROVED NEW DRUGS

Activity Date: October 10, 2022

Date Posted: October 25, 2022

Case Number: DC-18-0027-HL-O

Web Summary: OIG-WS-2023-301

An Amtrak Maintainer based in Newark, New Jersey, and a Trainer based in Sunnyside, New York, were terminated after their disciplinary hearings on October 4, 2022. The two former employees conspired with another employee, Keith Kovaleski, to sell misbranded and unapproved new drugs. The Maintainer violated company policies by ordering misbranded and/or unapproved new drugs from Kovaleski's company, All American Peptide (AAP), and by accepting shipments of these products on behalf of Kovaleski. The Trainer violated company policies by regularly ordering misbranded and/or unapproved new drugs from AAP and reselling them to the public. Kovaleski, an Assistant Foreman based in New York, is currently awaiting sentencing after pleading guilty on March 21, 2022, to selling misbranded and unapproved new drugs. The two former employees are ineligible for rehire.